Degenerative MR: Two Choices now for Mitral Transcatheter Repair (TEER): Clasp IID Trial

Degenerative MR: Two Choices now for Mitral Transcatheter Repair (TEER): Clasp IID Trial

Key Points from this trial:

The CLASP IID trial, the first randomized controlled trial comparing the PASCAL system and the MitraClip system in prohibitive-risk patients with significant symptomatic degenerative mitral regurgitation (DMR), aimed to report primary and secondary endpoints along with 1-year outcomes for the full cohort.

In the study, 300 patients were randomized (PASCAL: n = 204; MitraClip: n = 96).

At 1 year, differences in survival, freedom from heart failure hospitalization, and major adverse events (MAE) were nonsignificant (P > 0.05 for all).

The PASCAL system demonstrated noninferiority to the MitraClip system for primary endpoints, with 30-day MAE rates of 4.6% vs. 5.4% and 6-month MR ≤2+ rates of 97.9% vs. 95.7%.

Noninferiority was also met for secondary effectiveness endpoints at 1 year, with MR ≤2+ rates of 95.8% vs. 93.8% and MR ≤1+ rates of 77.1% vs. 71.3%.

Both groups showed sustained improvements in functional classification and quality of life (P < 0.05 for all vs. baseline).

The results affirm the PASCAL system as a beneficial therapy for prohibitive-surgical-risk patients with significant symptomatic DMR. Link to article: https://doi.org/10.1016/j.jcin.2023.10.002

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(35)

REDUCE-AMI Trial: Diminishing Role of Beta-Blockers in ACS with preserved LVEF

REDUCE-AMI Trial: Diminishing Role of Beta-Blockers in ACS with preserved LVEF

1. The REDUCE-AMI trial showed no significant benefit of beta-blockers in reducing all-cause mortality or future myocardial infarction in patients with acute myocardial infarction and preserved left v...

24 Kesä 20244min

Improving Left Ventricular Ejection Fraction in Heart Failure Patients: Insights from the HF-OPT Study

Improving Left Ventricular Ejection Fraction in Heart Failure Patients: Insights from the HF-OPT Study

The HF-OPT study investigated the improvement of left ventricular ejection fraction (LVEF) beyond 90 days in patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF). In this...

22 Kesä 20245min

AI in Cardiovascular Medicine: JACC Review

AI in Cardiovascular Medicine: JACC Review

Overview: This review discusses the use and future directions of AI in cardiology, focusing on areas like electrocardiography, telemetry and wearables, echocardiography, CMR, nuclear cardiology, CT, e...

21 Kesä 20246min

2024 ACC Peripheral Artery Disease (PAD) Guidelines

2024 ACC Peripheral Artery Disease (PAD) Guidelines

Collaborative vascular care is emphasized to address health disparities, gaps in medical therapy, structured exercise, and good foot care along with appropriate revascularization to prevent limb loss....

31 Touko 20246min

2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy

2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy

2024 HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise Mavacamten: Class 1 recommendation for symptomatic obstructive HCM. Exercise: Now allows for "vigorous" activity; competitive lev...

21 Touko 20249min

DOACs: When direct oral anticoagulants should not be used?

DOACs: When direct oral anticoagulants should not be used?

Key Points: Positive Aspects of DOACs: DOACs are acknowledged for their convenience, efficacy, and safety in conditions like atrial fibrillation (AF) and venous thromboembolism (VTE). The review sup...

29 Tammi 20244min

Cath: NPO vs Eating before Heart Cath

Cath: NPO vs Eating before Heart Cath

Background: Traditional practice requires fasting before cardiac catheterization, but there's no evidence to support it. Objective: This study compared a heart-healthy pre-procedure diet with fasting ...

26 Tammi 20243min

Stable CAD and Angina: PCI without medical therapy as first treatment (ORBITA-2)

Stable CAD and Angina: PCI without medical therapy as first treatment (ORBITA-2)

Key Points In patients not taking antianginal meds, PCI alleviated some—but not all—symptoms Background: Percutaneous coronary intervention (PCI) is commonly used to alleviate stable angina symptom...

22 Tammi 20243min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
tiedenaiset-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
psykopodiaa-podcast
terapiassa
meditaatiot-suomeksi
rss-pitaisko-erota
rss-seksicast
fitnessvastaanotto
paritellen
rss-kuumilla-aalloilla
junnut-pelissa
rss-pt-paahtio
rss-uplevel-by-sonja-hannus
selviytyjat-tarinoita-elamasta
rss-vapaudu-voimaasi
kehorauhaa
rss-rentoudu-podcast-rentoutumiseen-hanna-viljanmaa
onnen-kuplia
rss-sanelunpurku-podcast